Iron Deficiency Anemia in Inflammatory Bowel Disease Management

Iron deficiency anaemia (IDA) is the most common systemic complication of inflammatory bowel disease (IBD), arising from chronic intestinal blood loss, reduced dietary intake, malabsorption and inflammation-driven alterations in iron homeostasis. Patients with IBD frequently experience fatigue, diminished exercise capacity and impaired quality of life, yet IDA remains both underdiagnosed and undertreated. Effective management demands a systematic diagnostic workup that distinguishes IDA from anaemia of chronic disease and mixed aetiologies; this typically includes measurement of haemoglobin, ferritin, transferrin saturation and inflammatory markers such as C-reactive protein. Therapeutic strategies encompass oral iron supplementation for mild, quiescent disease and intravenous iron formulations for those with active inflammation, intolerance to oral preparations or inadequate response. Novel insights into the regulatory role of the peptide hormone hepcidin have illuminated mechanisms by which inflammation suppresses dietary iron absorption and iron release from stores, guiding personalised treatment algorithms. International guidelines advocate routine screening, tailored iron repletion and close monitoring of haematological response, yet heterogeneity in clinical practice underscores the need for increased awareness and standardised care pathways across global settings.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Iron Deficiency Anemia in Inflammatory Bowel Disease Management publication trend

The graph below shows the total number of articles in iron deficiency anemia in inflammatory bowel disease management across all publications each year (not limited to Nature Index journals).

Technical terms

Iron deficiency anaemia (IDA): A condition in which insufficient iron impairs haemoglobin synthesis, leading to reduced oxygen-carrying capacity and symptomatic fatigue.

Inflammatory bowel disease (IBD): Chronic inflammatory disorders of the gastrointestinal tract, primarily Crohn’s disease and ulcerative colitis, often complicated by extraintestinal manifestations such as anaemia.

Hepcidin: A liver-derived peptide hormone that regulates systemic iron balance by inhibiting intestinal iron absorption and iron release from macrophage stores, upregulated during inflammation.

Ferritin: An intracellular protein complex that stores iron; serum ferritin reflects body iron reserves but may be elevated as an acute-phase reactant in inflammation.

Transferrin saturation: The percentage of iron-binding sites on transferrin occupied by iron; a marker of circulating bioavailable iron.

References

1. Association between hepcidin levels and inflammatory bowel disease: A systematic review and meta‐analysis of observational studies. Food Science & Nutrition (2024).
2. Potential Diagnostic Role of Hepcidin in Anemic Patients Affected by Inflammatory Bowel Disease: A Systematic Review. Diagnostics (2024).
3. Rational Management of Iron-Deficiency Anaemia in Inflammatory Bowel Disease. Nutrients (2018).
4. High Prevalence but Insufficient Treatment of Iron‐Deficiency Anemia in Patients with Inflammatory Bowel Disease: Results of a Population‐Based Cohort. Gastroenterology Research and Practice (2012).
5. Iron Deficiency Anemia in Inflammatory Bowel Diseases—A Narrative Review. Nutrients (2021).